TY - JOUR
T1 - Underexpression of messenger RNA for peripheral myelin protein 22 in hereditary neuropathy with liability to pressure palsies
AU - Schenone, Angelo
AU - Nobbio, L.
AU - Mandich, P.
AU - Bellone, E.
AU - Abbruzzese, M.
AU - Aymar, F.
AU - Mancardi, G. L.
AU - Windebank, A. J.
PY - 1997/2
Y1 - 1997/2
N2 - Hereditary neuropathy with liability to pressure palsies (HNPP) is associated with a deletion in chromosome 17p11.2, including the gene for the peripheral myelin protein 22 (PMP-22). Because of the proposal that a decreased dosage of the PMP-22 gene was the cause of HNPP, we evaluated sural nerves from eight patients with the 17p11.2 deletion and from five normal controls. The relative amount of PMP-22 mRNA was significantly lower in HNPP patients compared with normal controls (p < 0.02) using a semiquantitative reverse transcriptase-polymerase chain reaction. There was no significant decrease of P(o) mRNA. Sural nerves from HNPP patients showed normal immunostaining with monoclonal antibodies against PMP-22, P(o), and myelin basic protein, and only rare myelinated fibers, classified as 'tomacula,' showed a patchy staining of the compact myelin with monoclonal antibody against PMP-22. The significant underexpression of PMP-22 mRNA in HNPP patients compared with normal controls demonstrates that a decreased dosage of the PMP-22 gene is the most likely pathogenetic mechanism in HNPP.
AB - Hereditary neuropathy with liability to pressure palsies (HNPP) is associated with a deletion in chromosome 17p11.2, including the gene for the peripheral myelin protein 22 (PMP-22). Because of the proposal that a decreased dosage of the PMP-22 gene was the cause of HNPP, we evaluated sural nerves from eight patients with the 17p11.2 deletion and from five normal controls. The relative amount of PMP-22 mRNA was significantly lower in HNPP patients compared with normal controls (p < 0.02) using a semiquantitative reverse transcriptase-polymerase chain reaction. There was no significant decrease of P(o) mRNA. Sural nerves from HNPP patients showed normal immunostaining with monoclonal antibodies against PMP-22, P(o), and myelin basic protein, and only rare myelinated fibers, classified as 'tomacula,' showed a patchy staining of the compact myelin with monoclonal antibody against PMP-22. The significant underexpression of PMP-22 mRNA in HNPP patients compared with normal controls demonstrates that a decreased dosage of the PMP-22 gene is the most likely pathogenetic mechanism in HNPP.
UR - http://www.scopus.com/inward/record.url?scp=0031035514&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031035514&partnerID=8YFLogxK
U2 - 10.1212/WNL.48.2.445
DO - 10.1212/WNL.48.2.445
M3 - Article
C2 - 9040736
AN - SCOPUS:0031035514
SN - 0028-3878
VL - 48
SP - 445
EP - 449
JO - Neurology
JF - Neurology
IS - 2
ER -